Phase 2 Clinical Trial of REOLYSIN in Combination with Gemcitabine in Pancreatic Cancer Reaches Primary Endpoint

The company will continue testing REOLYSIN with various chemotherapeutic agents across multiple trials to further understand its potential in the treatment of pancreatic cancer.

Oncolytics Biotech Inc. announced last week that interim data from a Phase 2 clinical trial using intravenous administration of REOLYSIN? in combination with gemcitabine (Gemzar?) in patients with advanced pancreatic cancer (REO 017) indicated that the clinical study had successfully reached its primary endpoint, and that the drug combination is active.

To date, eight patients of 13 evaluable patients in the study had stable disease (SD) for 12 weeks or longer, for a clinical benefit rate (complete response (CR) + partial response (PR) + SD) of 62%. An additional patient had an unconfirmed PR of less than six weeks.

The study is using a one sample, two-stage design. In the first stage, 17 patients were to be enrolled, and best response noted.  If less th